Spondyloarthritis

Is There an Association Between Psoriasis/PsA and Thyroid Disease?

Aside from autoimmunity, an analysis of the tie between psoriasis and thyroid diseases is provided.

Long-Term Efficacy and Safety of Tofacitinib in Patients With Psoriatic Arthritis Analyzed

In the final analysis of the OPAL Balance study, researchers assessed the safety, tolerability, and efficacy of tofacitinib in patients with active psoriatic arthritis.

Driving Difficulties Common Among Patients With Axial Spondyloarthritis

Researchers described driving difficulties among patients with axial spondyloarthritis and characterized clinical and sociodemographic features and impact on work.

Upadacitinib Beats Placebo for Psoriatic Arthritis

For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo.

GRAPPA 2020 Annual Meeting: Management of Psoriasis and Psoriatic Arthritis During the COVID-19 Pandemic

A plenary session at the 2020 GRAPPA Annual Meeting was focused on the perspectives of the management of psoriasis and psoriatic arthritis during the COVID-19 pandemic.

Low Rates of GI-Related Adverse Events in Patients With PsA and AS Initiating Secukinumab

Researchers evaluated gastrointestinal-related adverse events in patients with psoriatic arthritis and ankylosing spondylitis who were initiating secukinumab.

Continuing vs Withdrawing Ixekizumab in Patients With PsA With Stable Minimal Disease Activity

Investigators assessed the effect of withdrawing ixekizumab in patients with psoriatic arthritis with minimal disease activity after open-label ixekizumab treatment.

Premature Mortality Not Associated With Pain in Patients With Psoriatic Arthritis

Researchers sought to determine if a higher cumulative pain intensity is associated with premature mortality risk in patients with PsA.

Drug Retention, Remission, and Response Rates of Secukinumab in Psoriatic Arthritis Analyzed in Europe

Researchers assessed the overall real-life 6- and 12-month retention rates of secukinumab in patients with psoriatic arthritis in Europe. They also assessed remission, low-disease activity, and response rates of secukinumab.

Benefits of Guselkumab Observed Through 2 Years in Psoriatic Arthritis Trial

The DISCOVER-2 study aimed to evaluate multiple clinical outcomes including joint and skin symptoms and radiographic progression in patients with psoriatic arthritis.